These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19107520)

  • 1. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
    Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
    J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.
    Li X; Xiao L; Yang Y; Shen H; Zeng H; Wang Z
    J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):340-2. PubMed ID: 18563337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).
    Nemes K; Sebestyén A; Márk A; Hajdu M; Kenessey I; Sticz T; Nagy E; Barna G; Váradi Z; Kovács G; Kopper L; Csóka M
    PLoS One; 2013; 8(4):e59335. PubMed ID: 23573198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
    Li T; Yang Y; Li X; Xu C; Meng L
    Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.
    Bae-Jump VL; Zhou C; Boggess JF; Whang YE; Barroilhet L; Gehrig PA
    Gynecol Oncol; 2010 Dec; 119(3):579-85. PubMed ID: 20863555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the mTOR/4E-BP pathway in endometrial cancer.
    Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
    Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
    Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
    PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
    Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
    Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
    Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
    Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
    Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
    Zhang S; Wang M; Li Q; Zhu P
    Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
    Zhou C; Gehrig PA; Whang YE; Boggess JF
    Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
    No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS
    Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
    Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
    Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.